MS Consensus 2012: From Research to Practice

June 27, 2012

Activity Description
Management of multiple sclerosis is currently one of the most dynamic fields in neurology. Large-scale congresses, such as those held annually by the American Academy of Neurology, are prime opportunities to learn of the many worldwide contributions toward a better understanding of the MS disease process, additional data on the efficacy and safety of existing disease-modifying agents, the utility of newer imaging techniques, the discovery of new biomarkers, and the potential for improving patient care with emerging drug therapies. This educational program is intended to deliver highlights from the AAN, as well as other important and clinically relevant updates in MS management.

Learning Objectives
This activity is intended for neurologists and neurology nurses who manage patients with multiple sclerosis. At the conclusion of this activity, participants should be able to:   

• Discuss the most recent and clinically relevant research on the pathogenesis, risk factors, diagnosis, imaging techniques, and treatment of MS
• Describe the mechanisms of the available MS therapies and how their differences and similarities may affect their safety, efficacy, and long-term impact on clinical outcomes
• Differentiate emerging MS therapies with regard to their mechanisms, safety, efficacy, and immunological activity
• Outline key components of patient education including the impact of early treatment to deter disease progression and the importance of treatment adherence

Agenda
6:00 PM.................... Registration
6:30 PM.................... Dinner
7:00 PM.................... CME Presentation
8:30 PM.................... Adjourn
 
Faculty
Becky Jo Parks, MD
Associate Professor of Neurology
John L. Trotter MS Center
St. Louis, Missouri

CME Series Chair
Joy A. Derwenskus, DO
Assistant Professor of Neurology
Northwestern University
Chicago, Illinois

MS Nurse Consultant
Melanie Dumlao, RN, MS, ACNP, MSCN
Nurse Practitioner, Comprehensive MS Program
Northwestern University
Chicago, Illinois

This activity is supported by an educational grant from Teva Neuroscience.

Accreditation

Physicians:
This activity has been planned and implemented in accordance with the essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of ProCE, Inc. and the National Association of Managed Care Physicians (NAMCP). The NAMCP is accredited by the ACCME to provide continuing medical education (CME) to physicians. The NAMCP designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses:
Nursing credit is provided for this activity through collaboration between ProCE, Inc. and Wild Iris Medical Education, Inc., a provider of continuing education accredited by the American Nurses Credentialing Center's Commission on Accreditation. This activity provides 1.5 contact hours of nurse CE credit.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its
continuing education activities. Faculty must disclose to participants any significant relationships with companies that manufacture or market products discussed during their presentation. Faculty conflict of interest disclosure will be announced at the beginning of the CME activity. The planners of this activity have no real or perceived financial relationships to disclose.

Please note: The opinions expressed in this activity should not be construed as those of the CE/CME provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.